Pharmacogenetics and pharmacogenomics
- PMID:11411304
- DOI: 10.1016/s0031-3955(05)70338-2
Pharmacogenetics and pharmacogenomics
Abstract
This article introduces pharmacogenetics and pharmacogenomics in the context of pharmacotherapy in the pediatric ICU setting. As an independent discipline (if it can be considered as such), pediatric or developmental pharmacogenetics is essentially at a neonatal stage. Available pharmacokinetic data derived from studies of drugs that are largely dependent on a single CYP pathway for their elimination provide initial assessments of the developmental profile of that particular CYP isoform. Essentially then, pharmacogenetics in a pediatric context refers to the changes in phenotype that occur as a child grows and develops. Furthermore, the apparent drug biotransformation "phenotype" may be influenced by disease (infection), environmental factors (diet and environmental contaminants) and concurrent medications; however, drug response is a function of the complex interplay among genes involved in drug transport, drug biotransformation, receptors, and signal transduction processes, among others. Therefore, optimization of pediatric pharmacotherapy necessarily requires that developmental changes in each of these areas and not just drug biotransformation be investigated thoroughly before the promise of pharmacogenetics and pharmacogenomics for rational therapeutics can be realized in children.
Similar articles
- [Status of pharmacogenomics and its future role in drug therapy].Cascorbi I.Cascorbi I.Internist (Berl). 2002 Apr;43(4):506-10. doi: 10.1007/s00108-002-0558-0.Internist (Berl). 2002.PMID:12053407German.No abstract available.
- Kinetic characterization and identification of the enzymes responsible for the hepatic biotransformation of adinazolam and N-desmethyladinazolam in man.Venkatakrishnan K, von Moltke LL, Duan SX, Fleishaker JC, Shader RI, Greenblatt DJ.Venkatakrishnan K, et al.J Pharm Pharmacol. 1998 Mar;50(3):265-74. doi: 10.1111/j.2042-7158.1998.tb06859.x.J Pharm Pharmacol. 1998.PMID:9600717
- Sex differences in drug metabolism: cytochrome P-450 and uridine diphosphate glucuronosyltransferase.Anderson GD.Anderson GD.J Gend Specif Med. 2002 Jan-Feb;5(1):25-33.J Gend Specif Med. 2002.PMID:11859684Review.
- Human cytochrome P450s: selectivity and measurement in vivo.Smith DA, Abel SM, Hyland R, Jones BC.Smith DA, et al.Xenobiotica. 1998 Dec;28(12):1095-128. doi: 10.1080/004982598238859.Xenobiotica. 1998.PMID:9890156Review.No abstract available.
- Quinidine as a probe for CYP3A4 activity: intrasubject variability and lack of correlation with probe-based assays for CYP1A2, CYP2C9, CYP2C19, and CYP2D6.Damkier P, Brøsen K.Damkier P, et al.Clin Pharmacol Ther. 2000 Aug;68(2):199-209. doi: 10.1067/mcp.2000.108532.Clin Pharmacol Ther. 2000.PMID:10976551Clinical Trial.
Cited by
- A quarter century of progress in paediatric clinical pharmacology: A personal view.MacLeod SM.MacLeod SM.Br J Clin Pharmacol. 2016 Feb;81(2):228-34. doi: 10.1111/bcp.12776. Epub 2015 Nov 10.Br J Clin Pharmacol. 2016.PMID:26344707Free PMC article.No abstract available.
- The impact of prescribed psychotropics on youth.Lakhan SE, Hagger-Johnson GE.Lakhan SE, et al.Clin Pract Epidemiol Ment Health. 2007 Oct 20;3:21. doi: 10.1186/1745-0179-3-21.Clin Pract Epidemiol Ment Health. 2007.PMID:17949504Free PMC article.
- Randomized, open-label, multicentre pharmacokinetic studies of two dose levels of pantoprazole granules in infants and children aged 1 month through <6 years with gastro-oesophageal reflux disease.Tammara BK, Sullivan JE, Adcock KG, Kierkus J, Giblin J, Rath N, Meng X, Maguire MK, Comer GM, Ward RM.Tammara BK, et al.Clin Pharmacokinet. 2011 Aug;50(8):541-50. doi: 10.2165/11591900-000000000-00000.Clin Pharmacokinet. 2011.PMID:21740077Clinical Trial.
- TheCyp2b6 Gene Polymorphism and Phenotypic Correlation of Efavirenz-Based Combination Therapy Among the Niger Delta Ethnic Population: Implications in Modern Pharmacogenomics.Bunu SJ, Owaba ADC, Vaikosen EN, Ebeshi BU.Bunu SJ, et al.Pharmgenomics Pers Med. 2022 Jan 25;15:45-54. doi: 10.2147/PGPM.S345038. eCollection 2022.Pharmgenomics Pers Med. 2022.PMID:35115810Free PMC article.
- The interactions of age, genetics, and disease severity on tacrolimus dosing requirements after pediatric kidney and liver transplantation.de Wildt SN, van Schaik RH, Soldin OP, Soldin SJ, Brojeni PY, van der Heiden IP, Parshuram C, Nulman I, Koren G.de Wildt SN, et al.Eur J Clin Pharmacol. 2011 Dec;67(12):1231-41. doi: 10.1007/s00228-011-1083-7. Epub 2011 Jun 23.Eur J Clin Pharmacol. 2011.PMID:21698374Free PMC article.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Research Materials